GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Cyclically Adjusted Revenue per Share

Agenus (FRA:AJ8) Cyclically Adjusted Revenue per Share : €14.51 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Agenus's adjusted revenue per share for the three months ended in Mar. 2024 was €25.309. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €14.51 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Agenus's average Cyclically Adjusted Revenue Growth Rate was 27.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 17.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Agenus was 21.70% per year. The lowest was -11.20% per year. And the median was 4.70% per year.

As of today (2024-05-24), Agenus's current stock price is €7.80. Agenus's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €14.51. Agenus's Cyclically Adjusted PS Ratio of today is 0.54.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Agenus was 31.53. The lowest was 0.30. And the median was 9.79.


Agenus Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Agenus's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Cyclically Adjusted Revenue per Share Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.98 6.77 10.15 9.48 12.63

Agenus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.96 12.35 12.63 12.63 14.51

Competitive Comparison of Agenus's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Agenus's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Cyclically Adjusted PS Ratio falls into.



Agenus Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agenus's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=25.309/131.7762*131.7762
=25.309

Current CPI (Mar. 2024) = 131.7762.

Agenus Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.723 100.560 0.947
201409 0.386 100.428 0.506
201412 0.418 99.070 0.556
201503 1.096 99.621 1.450
201506 1.488 100.684 1.948
201509 1.443 100.392 1.894
201512 1.649 99.792 2.178
201603 1.235 100.470 1.620
201606 1.349 101.688 1.748
201609 0.908 101.861 1.175
201612 1.209 101.863 1.564
201703 5.391 102.862 6.906
201706 0.755 103.349 0.963
201709 0.564 104.136 0.714
201712 1.398 104.011 1.771
201803 0.259 105.290 0.324
201806 2.589 106.317 3.209
201809 1.908 106.507 2.361
201812 0.943 105.998 1.172
201903 9.516 107.251 11.692
201906 2.066 108.070 2.519
201909 2.631 108.329 3.200
201912 4.504 108.420 5.474
202003 1.888 108.902 2.285
202006 2.829 108.767 3.427
202009 1.379 109.815 1.655
202012 2.663 109.897 3.193
202103 0.983 111.754 1.159
202106 0.799 114.631 0.919
202109 17.430 115.734 19.846
202112 1.397 117.630 1.565
202203 1.824 121.301 1.982
202206 1.429 125.017 1.506
202209 1.604 125.227 1.688
202212 1.760 125.222 1.852
202303 26.974 127.348 27.912
202306 1.329 128.729 1.360
202309 1.205 129.860 1.223
202312 4.002 129.419 4.075
202403 25.309 131.776 25.309

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Agenus  (FRA:AJ8) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Agenus's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.80/14.51
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Agenus was 31.53. The lowest was 0.30. And the median was 9.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Agenus Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Agenus's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (FRA:AJ8) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines